Business
Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors
PHILADELPHIA & SAN FRANCISCO, November 04, 2025--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb ("BMS") to support the development of Dispatch’s DISP-10 program. Under the agreement, BMS will provide idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T therapy, for use in Dispatch’s first U.S. Phase 1 trial, expected to in
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/d9e4df3e6c0fa655ee4d319afa56a5e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZNSJqBb9Q11cMWXwN45C7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d9e4df3e6c0fa655ee4d319afa56a5e7","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/1T7W33e36erSE9Iuuzd57w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/d9e4df3e6c0fa655ee4d319afa56a5e7","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Bristol Myers Squibb to provide idecabtagene vicleucel (ide-cel) for Dispatch’s planned U.S. Phase 1 study, expected to initiate in 2026","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"Collaboration to accelerate DISP-10 in development for patients with solid tumors of epithelial origin, covering 90% of all solid tumor cancers","length":143,"tagName":"p","attribs":{}},{"type":"text","content":"First-of-its-kind clinical supply agreement for an autologous CAR T-cell therapy","length":80,"tagName":"p","attribs":{}},{"type":"text","content":"PHILADELPHIA & SAN FRANCISCO, November 04, 2025--(BUSINESS WIRE)--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb ("BMS") to support the development of Dispatch’s DISP-10 program. Under the agreement, BMS will provide idecabtagene vicleucel (ide-cel), a BCMA-directed CAR T therapy, for use in Dispatch’s first U.S. Phase 1 trial, expected to initiate in 2026.","length":546,"tagName":"p"},{"type":"text","content":"DISP-10 is a novel, investigational product with two components, designed to overcome the challenges of treating solid tumors. The first component, DV-10, is a tumor-specific virus engineered to deliver a modified form of the B-cell maturation antigen (dBCMA), along with IL-18 and CXCL-9, to "paint" a synthetic antigen onto tumor cells, reengineer the tumor microenvironment to support T cell function and enhance T cell migration into the tumor. ...